Clinical trial · Interventional
Efficacy of Mosapride on Recovery of Intestinal Motility After Elective Colorectal Cancer Surgery
Randomized Controlled Trials of Efficacy of Mosapride on Recovery of Intestinal Motility After Elective Colorectal Cancer Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Postoperative ileus (POI) is one of the most common causes of prolonged hospital stays after abdominal surgery. The pathophysiology of POI is multifactorial and complex.It is known to be associated with sympathetic neural reflexes,local and systemic inflammatory mediators,and changes invarious neural and hormonal transmitters.Sympathetic (adrenergic) hyperactivity results in reduction of propulsive motility,and an increase in sphinctertone.Parasympathetic (cholinergic) hypoactivity results in adecrease in gastrointestinalmotility. Various agents called prokinetic drugs,including erythromycin, metoclopramide, cholinergic agents have been assessed in an effort to improved gastrointestinal motility. Mosapridecitrate is another prokinetic drug that selectively activates 5-HT4 receptors. Mosapride stimulates serotonin receptor in the digestive tract and increases acetylcholine release to promote upper digestive tract (stomach and duodenum) and lower digestive tract (colon) motility and gastric emptying without cardiac side effects. We therefore investigate the effect of mosapride on postoperative gastrointestinal motility after open and laparoscopic colectomy in a prospective randomized, controlled study in patients under going colectomy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bowel Ileus | — | UNRESOLVED | — |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Mosapride | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- The mosapride group
- description
- The mosapride group received 15 mg of mosapride by mouth or feeding via NG with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized.
- interventionNames
- Drug: Mosapride
- type
- PLACEBO_COMPARATOR
- label
- The control group
- description
- The control group received 15 mg of placebo drug with 50 ml of water three times a day, starting on the morning of postoperative day 1, until hospital discharge or for a maximum of 10 postoperative days if the patient remained hospitalized.
- interventionNames
- Drug: Placebo
Primary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who are undergoing elective colorectal cancer surgery at Ramathibodi hospital both open and laparoscopic surgery. * Both male and female who age between 15 to 70 years old. * Physical status American Society of Anesthesiologists (ASA) classification1-2-3. Exclusion Criteria: * Metastatic disease. * Patients who reject to participate or withdrawal from the research. * History of Mosapride allergy. * Pregnancy. * Emergency colorectal cancer surgery. * Intestinal perforation or obstruction. * Patients who have cardiac problem (Side effects of Mosapride may include arrhythmia or QTprolong). * Physical status American Society of Anesthesiologists (ASA) classification 4-5.
References
Publications (1)
- DERIVEDThampongsa T, Saengsawang B, Supsamutchai C, Wilasrusmee C, Jirasiritham J, Punmeechao P, Palitnonkiat V, Poprom N, Choikrua P, Singhathas P. The efficacy of mosapride on recovery of intestinal motility after elective colorectal cancer surgery: a randomized controlled trial. Ann Coloproctol. 2025 Jun;41(3):232-238. doi: 10.3393/ac.2024.00892.0127. Epub 2025 Jun 25. PMID 40598989